NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

It is worse than that.

The Poly-ICLC arm only had 5 GBM patuents (the trial design was for both GBM and grade 3 gliomas). In the GBM patients the data showed:

. The OS P value was .78
. The 5 year OS in the Poly-ICLC arm was 0%
. The 3 year OS in the Poy-IICLC arm was 20%

[All the above from figure 3]

Not all that impressive for the 5 GBM patients treated with the combo.

And never forget that the process used to create the DC was very different from -L. They can call it "the same" all they want, but RA's would have a bit of an issue.